A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.
TB-500 (Thymosin Beta-4)
Investigational Actin-Binding Peptide Fragment
Compound Specifications
TB-500 (Thymosin Beta-4)
Investigational Actin-Binding Peptide Fragment
TB-500 is a synthetic peptide containing the active domain of Thymosin Beta-4, a naturally occurring protein studied in preclinical models for its involvement in cellular motility, actin regulation, and experimental tissue repair pathways.
In laboratory research, Thymosin Beta-4 active domain has been observed to bind actin, potentially supporting cell migration, endothelial cell organization, and localized tissue repair responses.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Subcutaneous administration 2 times weekly during recovery cycles.
Frequently Asked Clinical Questions
How does TB-500 differ from BPC-157?
Preclinical literature evaluates TB-500 (Thymosin Beta-4 active domain) for cellular migration and actin-binding pathways, whereas BPC-157 is primarily studied for microvascular and cytoprotective mechanisms.
How is TB-500 evaluated by medical providers?
Licensed providers evaluate each patient's injury background, laboratory biomarkers, and recovery timeline before determining if peptide therapy is clinically appropriate.